We have developed an automated assay to enumerate and characterize circulating multiple myeloma cells (CMMC) from peripheral blood of patients with plasma cell disorders. CMMC show expression of genes characteristic of myeloma and fluorescence in situ hybridisation results on CMMC correlated well with bone marrow results. We enumerated CMMC from over 1000 patient samples including separate cohorts of newly diagnosed multiple myeloma and high/intermediate risk smouldering multiple myeloma (SMM) with clinical follow-up data. In newly diagnosed myeloma patient samples, CMMC counts correlated with other clinical measures of disease burden, including the percentage of bone marrow plasma cells, serum M protein, and International Staging System stage. CMMC counts decreased significantly from baseline when a remission was achieved due to treatment (P < 0Á001). Patients with CMMC counts ≥100 at remission showed reduced survival relative to patients with CMMC counts <100. Patients with undetectable CMMC in remission showed further overall survival benefits. In the SMM cohort, there was a trend toward higher CMMC in patients with higher-risk myeloma precursor states. Significantly higher CMMC counts were observed between intermediate/high risk SMM patients that progressed versus those without progression (P = 0Á031). CMMC allow a non-invasive means of monitoring tumour biology and may have use as a prognostic test for patients with plasma cell disorders.
Multiple myeloma (MM) is the second most common haematological cancer in the US, where the estimated incidence of new cases of myeloma per year is over 20 000 (Rajkumar & Kumar, 2016) . Recent advances in MM treatments using agents such as immunomodulatory drugs and proteasome inhibitors, as well as newer antibody therapies, such as daratumumab and elotuzumab, have resulted in improved survival for patients with MM. Unfortunately, despite these advances, MM remains incurable with a 5-year survival rate of only 45% (Rajkumar & Kumar, 2016) . MM typically progresses through various stages of disease, from monoclonal gammopathy of undetermined significance (MGUS), through low and high risk smouldering MM (SMM), early active MM to fully symptomatic MM (Bories & Jagannath, 2014; Fulciniti et al, 2015; Glavey & Leung, 2015; Rajkumar et al, 2015) . Staging of the disease mainly depends on two diagnostic tests: non-invasive detection of paraproteins in the urine or blood and an invasive bone marrow biopsy aimed to estimate the percentage of bone marrow occupied by plasma cells (PC), as well as characterization of genomic abnormalities of plasma cells (Ghobrial & Landgren, 2014) . As the vast majority of MM patients can be monitored with serum and urine studies, bone marrow biopsies are done infrequently in the course of standard care.
However, this practice misses the opportunity to interrogate the genomics of the disease during repeated relapses, which could improve our understanding of the biology of the disease and identify potential actionable mutations for targeted therapy. Non-invasive access to tumour cells in the circulation would be a major advance for this purpose.
There is a growing body of evidence showing the presence of circulating MM cells (CMMC) in blood of not only patients with MM but also in those with the precursor states of MGUS and SMM (Billadeau et al, 1996) . Therefore, it may be possible to use these circulating cells as a liquid biopsy to better understand the tumour without the need for a bone marrow biopsy. Initial exploratory studies suggested that indeed, the presence of CMMC is considered an unfavourable prognostic factor and indicates an aggressive form of the disease (Paiva et al, 2013; An et al, 2015) , and therefore detecting CMMC can be used as a powerful prognostic tool in myeloma (Peceliunas et al, 2012) . CMMC in MM patients are often detected using flow cytometry with CD138 (also termed SDC1) as the principle marker (Peceliunas et al, 2012; Paiva et al, 2013; An et al, 2015) ; however despite significant recent efforts (such as the creation of the EuroFlow Consortium) the utility of flow cytometry has been limited by the challenge of standardizing instruments and detection markers across facilities, companies and geographies (Kalina et al, 2015) . This challenge of standardization is particularly critical when flow cytometry is used for minimal residual disease (MRD) assessment (Rawstron et al, 2016) . Moreover, for detection of rare cells, flow cytometry may not have sufficient sensitivity. It was previously estimated that, if the frequency of CMMC is 1 in 10 6 leucocytes, at least 15 705 214 nucleated events must be acquired by a flow cytometer to pinpoint 10 cells of interest with 95% confidence. It has been determined that the routine limit of detection for rare cells using a flow cytometer is approximately 1 in 10 5 (Allan & Keeney, 2010) . Therefore, plasma cell enumeration in peripheral blood is beyond the practical limits of what can be achieved using flow cytometers. A different methodology may be useful for sensitive, standardized detection of CMMC across plasma cell disease. A similar challenge of detecting rare circulating tumour cells (CTCs) in blood of patients with solid tumours was solved when the automated CELLSEARCH â system was developed and received US Food and Drug Administration (FDA) approval for clinical use in breast, prostate and colorectal cancer (Cristofanilli et al, 2004; Cohen et al, 2008; De Bono et al, 2008) . Here, we describe the development of a kit for the CELLSEARCH â platform that is capable of reproducibly isolating CMMCs from the peripheral blood of patients with plasma cell disorders. We also show that it is possible to further characterize tumour CMMC by fluorescence in situ hybridisation (FISH) and next generation sequencing (NGS). This may help to both better understand disease mechanisms and to improve the prognostic utility of CMMC in patient disease. Finally, we used CMMC enrichment technology in clinical studies of patients with newly diagnosed MM and intermediate/high risk SMM. We demonstrate that CMMC enumeration workflow on CELLSEARCH â offers more sensitivity (when compared to flow cytometry), easily standardized protocols and performance that its highly competitive with traditional clinical biomarkers in predicting clinical response while also allowing for subsequent non-invasive cytogenetic and molecular assessment that is concordant to that obtained using invasive procedures.
Methods

Patient cohorts
A The newly diagnosed MM cohort samples were collected as part of the CoMMpass study (ClinicalTrials.gov identifier: NCT01454297) which is an observational, longitudinal study to monitor the molecular profiles and clinical characteristics of newly diagnosed myeloma during the course of the disease. Blood for CMMC analysis was collected at baseline, during remission (defined as suspected complete response) and at relapse or progression of disease. Patient characteristics for this cohort are described in Table SI . For this cohort, CMMC were captured using CD138 and CD38 ferrofluids.
The intermediate/high risk SMM cohort samples were collected as part of the Siltuximab study in intermediate/high risk SMM (ClinicalTrials.gov Identifier: NCT01484275). Clinical biomarkers were used to classify the SMM cohort in the ultra-high risk group (≥60% bone marrow plasma cells or FLC ratio ≤0Á01 or ≥100), high risk group (not ultra-high risk group and ≥10% bone marrow plasma cells and serum M-protein ≥30 g/l) or the intermediate risk group (not ultrahigh risk group and ≥ 10% bone marrow plasma cells and serum M-protein <30 g/l but ≥10 g/l and FLC ratio <0Á126 or >8). For this cohort, CMMC were captured using CD138 ferrofluid. Baseline (pre-treatment) samples were analysed for CMMC counts and CMMC FISH from patients in treatment and control arms of the study. Patients in the control arm of the study only were monitored for disease progression based on a novel composite endpoint termed progressive disease indicator rate (PDIR), which is built from early signs of progression from SMM to active MM. Patients who present with a PDIR meet any of the following requirements within 6 months of the start of the study: CRAB (increased calcium level, renal dysfunction, anaemia and destructive bone lesion) criteria as defined by the International Myeloma Working Group (Rajkumar et al, 2014) , 25% increase in serum Mprotein relative to baseline at 2 consecutive assessments, unequivocal increase in bones lesions by magnetic resonance imaging, 25% decrease of 2 non-affected Ig's (IgG, IgM, IgA) at 2 consecutive assessments (immunoparesis), haemoglobin decrease of 15 g/l with 1 read below lower limit of normal and no other identifiable cause. Comparison of PDIR and clinical biomarkers (CMMC, M-protein, percent plasma cells) were performed using patients from the placebo arm of the study only to exclude the effects of treatment.
CMMC sample preparation
Peripheral blood was collected in CellSave tubes (Menarini Silicon Biosystems, Inc.) and shipped to Menarini Silicon Biosystems laboratories for enrichment. An aliquot (4Á0 ml) of blood was mixed with 10 ml of buffer, centrifuged at 800 g for 10 min, and then placed on the CELLTRACKS â AUTOPREP 
Sample analysis
The MAGNEST â was placed on the CELLTRACKS â ANA-LYZER II â , a four-colour semi-automated fluorescence microscope, and image frames covering the entire surface of the cartridge for each of the four fluorescent filter cubes were captured. Putative CMMC were ranked based on staining and morphology parameters using BioMarQ software (Menarini Silicon Biosystems, Inc.). CMMC were defined as events with round to oval morphology, a visible nucleus (DAPI positive), positive staining for CD38 and negative staining for CD45 and CD19. Images were scored as CMMC by trained operators. Results of cell enumeration are always expressed as the number of cells per 4Á0 ml of blood.
Accuracy, sensitivity, linearity and reproducibility of myeloma cell detection
For accuracy, linearity and sensitivity experiments, H929 cells were spiked into 4Á0 ml of blood collected into CellSave Preservative Tubes (Menarini Silicon Biosystems, Inc.) at 5 different levels of cells (0, 10, 100, 500 and 2000) . The exact number of cells spiked into blood was determined by flow cytometry. The samples were processed after spiking the blood on a CELLTRACKS â AUTOPREP â and analysed with a CELLTRACKS â ANALYZER II â . Sample testing was performed over two different days with a total of 5 different samples at each cell level. For reproducibility experiments, 500 H929 cells were spiked into 4Á0 ml of blood collected into CellSave preservative tubes from a total of 12 samples. Cell spikes and sample processing was as described above.
FISH analysis of CMMC
Following enrichment as described above, CMMC were fixed in the cartridge, hybridised overnight and imaged as previously described (Swennenhuis et al, 2009) . A three probe FISH assay was developed to simultaneously detect deletion of 17p (del17p) and two translocations of the IGH locus t (4;14)(p16;q32) and t(14;16)(q32;p23). Dual fusion type assays were prepared for the translocations using fluorescent labelled probes from Leica Biosystems (Buffalo Grove, IL, USA. The 14q32 probe was labelled with PlatinumBright 550, the 16p23 probe was labelled with PlatinumBright 415 and the 4p16 probe was labelled with PlatinumBright 647. The 17p probe was made repeat-free from BAC clone CTD-3054O5 as described (Swennenhuis et al, 2012) , and labelled with digoxygenin. Detection of the 17p probe was performed using anti-digoxygenin conjugated to fluorescein isothiocyanate (FITC; Roche Diagnostics Corporation, Indianapolis, IN, USA). Fifty or more CMMC were scored from each sample when possible. In cases where there were less than 50 CMMC present, all CMMC were scanned. Samples with ≥10 CMMC with evaluable FISH signals were considered for comparison to bone marrow results. Assay cut-offs were expressed as percentage of CMMC that contained abnormal FISH signals. CMMC FISH assay cut-offs were set based on development work using healthy donors and patient samples that were negative by bone marrow FISH. The cut-off for the del17p was set at 53% of CMMC with single 17p signal, no centromere 17 probe was used. The cut-offs for t(4;14) and t (14;16) were set at ≥10% of CMMC with two fusion signals or ≥75% of CMMC with a single fusion signal.
RNASeq of pure CMMC
For three donors, an aliquot of blood preserved in CellSave was used to enumerate the number of CMMC while a second aliquot of EDTA blood was used to evaluate a novel method of molecular profiling. In this approach, 4 ml blood was enriched using CD138 and CD38 ferrofluids on the AUTOPREP â with no permeabilisation of the cells. CMMC were subsequently stained using CD38 ( 
Bone marrow analysis
Bone marrow aspirates were obtained at the time of study enrolment for the newly diagnosed myeloma cohort. DNA and RNA were isolated from bone marrow isolates and NGS analysis was performed centrally at TGen, Phoenix, AZ, USA. A SeqFISH algorithm (Miller et al, 2016 ) was used to make calls for t(4:14), t(14;16) and del17p mutations in bone marrow and results were downloaded from the MM Research Foundation (MMRF) Researcher Gateway (www.research.themmrf.org). Bone marrow FISH for the high risk SMM cohort study was performed prior to treatment by the affiliated study institutions using standard methods and the results reported according to site guidelines.
Results
Development of CMMC assay
The CELLSEARCH â platform has been shown to be a highly reproducible method for enrichment of rare circulating epithelial tumour cells from blood Cristofanilli et al, 2004 and CD19 in CMMC. To demonstrate the precision of the assay, the human MM cell line H929 was spiked into blood from healthy donors, enriched and scored. Over 12 samples with varying numbers of H929 cells spiked into whole blood, an average of 61% (standard deviation 18%) of the spiked in cells were recovered. Recovery was linear over the range of 0-2000 cells with a correlation coefficient of 0Á98 (Fig 2B) .
To verify the design of the CMMC kits and methods kits we collected a cohort of whole blood samples from healthy donors, MGUS, SMM and MM patients (see verification cohort description in materials and methods). The cohort reflects a mixture of all disease and treatment states. Figure 2C shows the CMMC counts for the different patient populations and kit configurations. For kit configuration 1, one or more CMMC was detected in 56%, 100% and 84% of MGUS, SMM, and MM patients respectively. For kit configuration 2, one or more CMMC was detected in 86%, 95% and 86% of MGUS, SMM, and MM patients respectively. For both kit configurations, most of the healthy donors showed zero CMMC (67% and 87% for kit 1 and kit 2 respectively) and no healthy donors had more than six events scored as CMMC. Median CMMC counts increased with advancing disease state with the exception of the myeloma patients. This is probably due to a number of patients in this cohort being treated for their disease, thereby reducing the number of CMMC.
As the CMMC assay does not contain markers that can definitively characterize these cells as malignant, we developed methods to perform FISH and transcriptional profiling of CMMC.
For the FISH analysis we developed a three probe assay to simultaneously detect del17p, t(4,14) and t(14;16) in CMMC. The FISH assay was tested in myeloma cell lines U266, H929 and MM1s and showed the expected del17p, t(4,14) and t (14;16) mutations, respectively (data not shown). The CMMC FISH assay was also tested on normal leucocytes from healthy donor and patient samples to set assay cut-offs. Genomic alterations were detected in the CMMC from this cohort. Figure 2D shows a representative image of a CMMC from a SMM patient from the verification cohort that harboured a 17p deletion and a normal leucocyte.
To further verify the tumour origin of CMMC we isolated pools of individually captured CMMC from patients and Figure 2E shows log 2 transformed, normalized FPKM (Fragments Per Kilobase of transcript per Million mapped reads) values for selected expressed genes from the CMMC, leucocytes and cell lines. We found that captured CMMC expressed genes that were consistent with the myeloma cell lines, such as proliferation markers CCND1 and CCND2, plasma cell markers SLAMF7 and SDC1 (CD138), and nuclear factor jB (NFKB) pathway genes CD74 and BIRC3, all of which have previously been linked to myeloma (Demchenko et al, 2010; Frigyesi et al, 2014 
CMMC in newly diagnosed multiple myeloma
To explore the utility of the assay in newly diagnosed MM we collected blood from patients enrolled in the MMRF CoMMpass trial, a longitudinal study to monitor clinical biomarkers throughout progression of newly diagnosed MM. CMMC were collected at baseline, during remission and at disease relapse. CMMC counts and characteristics were compared to other clinical measurements collected as part of the study. Figure 3A shows that CMMC were detected in 98% of newly diagnosed MM patients and the median number of CMMC was 1111/4 ml blood (range 0-47 146). Patients that achieved a remission in response to therapy had much lower CMMC counts (median 5, range 0-29 195) than baseline, and patients that had relapsed had elevated CMMC levels (median 131Á5, range 0-29 821). Serial CMMC measurements were available for a subset of patients in this cohort. For patients with both baseline and remission CMMC measurements (n = 68), CMMC levels dropped an average of 2 logs (median 99Á1%) (Fig 3B) .
To verify the utility of CMMC as a biomarker for tracking the disease, CMMC analysis was compared to a number of standard blood and bone marrow assays. A significant correlation was seen between baseline CMMC counts and International Staging System (ISS) stage which reflects blood beta 2-microglobulin and albumin levels. CMMC count distributions are significantly increased in ISS stage 2 (P = 4Á03 9 10 À6 ) and stage 3 (P = 1Á45 9 10
À10
) relative to ISS stage 1 (Fig 3C) . CMMC counts showed a statistically significant association with serum M protein levels (associated P-value 4Á55 9 10 À11 , Fig 3D) . Likewise, CMMC counts showed a significant association and strong correlation with the percentage of bone marrow plasma cells, as measured by flow cytometry (associated P-value 9Á9 9 10 À6 , Fig 3E) .
CMMC counts showed a significant association with the percentage of plasma cells in peripheral blood as measured by flow cytometry (associated P-value 1Á87 9 10 À45 , Fig 3F) . It is interesting to note that there was a large number of patients for which no plasma cells were detectable by flow cytometry in the bone marrow, and particularly, the blood, both of which do contain measureable amounts of CMMC. This can be due to difficulty in sampling bone marrow and the relatively low frequency of CMMC in the circulation that makes detection difficult without enrichment.
To demonstrate the utility of CMMC as a means to gather genomic information about the tumour, we performed the CMMC FISH assays on a subset of samples that were determined to be positive for t(4;14), (14;16) or del17p based on bone marrow analyses. Bone marrow was analysed by Seq-FISH as described in the methods and the percent agreement of the CMMC FISH results and the bone marrow SeqFISH results were determined (Table I ). The CMMC FISH results agreed with bone marrow FISH results 88%, 94% and 84% of the time for the t(4;14), (14;16) and del17p assays. An analysis of the discordant bone marrow and CMMC FISH results showed that these samples had CMMC FISH results that were close to the assay cut-offs for the translocation probes or had karyotypic evidence of aneuploidy, which may be missed by the del17p FISH assay (Table SII ). Further refinement of the CMMC FISH assays and cut-off values would probably yield higher concordance with bone marrow. Additionally, it is also possible that the discrepancies between bone marrow and CMMC FISH results could be due to subclonal populations of malignant cells that are differentially present in either the bone marrow or peripheral blood compartment.
Survival data was available for a subset of patients in this cohort. Patients with greater than the median baseline CMMC count showed significantly inferior progression-free survival (PFS) relative to those below the median CMMC count (log rank P-value = 1Á95 À3 ) and a trend toward association with overall survival (OS) (log rank P-value = 0Á11). Patients whose CMMC counts were above the median value at the relapse measurement showed association with poorer PFS and OS (log rank P-values: PFS 1Á57 9 10 À2 , OS 1Á95 9 10 À2 ). Patients who had greater than the median remission CMMC count showed a trend for poorer PFS and statistically significant poorer OS than those with CMMC counts less than the median (log rank P-values: PFS 9Á68 9 10 À2 , OS 5Á78 9 10 À4 ). To further explore the utility of a CMMC measurement in remission we stratified patients into groups with remission CMMC counts that had the highest CMMC counts (<100 CMMC, n = 11, 8% of patients) and patients for whom no CMMC could be detected in remission (n = 24, 18% of patients). In this model, remission CMMC counts showed a higher association with PFS (Log rank P = 3Á89 9 10 À7 ) and OS (Log rank P = 5Á26 9 10 À3 ; Fig 4) . It is important to note that none of the 24 patients with undetectable CMMC at their remission measurement had died as of the time of analysis (median time to progression 770 days). No significant relationship with PFS or OS was found between the change in CMMC between baseline and remission.
CMMC in intermediate/high risk smouldering myeloma
To demonstrate the utility of the assay in a premalignant setting, CMMC measurements were collected from a cohort of intermediate and high risk SMM patients (n = 85, cohort described in methods and Table SIII) . CMMC were detected in 93Á7% of the intermediate/high risk SMM patients at baseline with a median of 100 CMMC/4 ml blood (range 0-47 370). Using a negative binominal regression model, CMMC counts were found to be elevated in high risk (P = 0Á261) and ultra-high risk (P = 3Á85 9 10 À7 ) SMM relative to intermediate risk SMM patients (Fig 5A) .
We also compared baseline CMMC measurements to standard clinical tests used to predict the progression from SMM to active myeloma (Fig 5B-E) . Baseline CMMC counts were statistically significantly elevated in patients whose disease ultimately progressed (P = 0Á031), whereas elevated M protein, percent plasma cells in bone marrow, and free light chain ratio showed a trend but did not reach statistical significance (P = 0Á068, 0Á071, 0Á100 respectively.) Area under the curve/receiver operating characteristic (AUC/ROC) analysis (Fig 5F) showed that baseline CMMC (AUC 0Á745) was at least as good a predictor of disease progression as Mprotein (AUC = 0Á687), percent bone marrow plasma cells (AUC = 0Á684) and free light chain ratio (AUC = 0Á668). Bone marrow FISH results were available for a subset of patients in this cohort. In cases where bone marrow FISH was available and CMMC FISH could be performed, CMMC FISH results showed good concordance with bone marrow FISH results for the three assays tested (Table I) .
Discussion
An ideal diagnostic approach for monitoring plasma cell disorders should be non-invasive, provide a quick readout of the disease state, and also allow the ability to perform detailed molecular profiling of the tumour. We have demonstrated that CMMC have the potential to address these diagnostic and research needs across the spectrum of plasma cell disorders.
We have developed methods to enrich CMMC from the peripheral blood of patients with plasma cell disorders using the highly reproducible and clinically validated CELLSEARCH â platform. We developed two capture reagent configurations to enrich for CMMC using CD138 antibody alone or a CD138/CD38 antibody combination. The best capture antigen(s) to enrich plasma cells is an open topic for discussion. It has been reported that down-regulation of CD138 or CD38 expression may occur in MM under certain conditions, such as some therapeutic treatments (Ise et al, 2016; Muz et al, 2016) . Further, Frigyesi et al (2014) showed that CD138 levels on malignant plasma cells decrease during storage of samples due to antigen shedding. This phenomenon Horizontal dashed lines indicate the optimum threshold for sensitivity versus specificity calculated using Youden's J statistic. Three patients (blue dots) with greater than 60% plasma cells in bone marrow at baseline were excluded from P-value calculations because these patients could be considered myeloma. (F) Area under the curve/receiver operating characteristic (AUC/ROC) analysis comparison of baseline CMMC, M-proteins, percent plasma cells in bone marrow, and FLC ratio. CMMC, circulating multiple myeloma cells; FLC, free light chain; N, no; PDIR, progressive disease indicator rate; SMM, smouldering multiple myeloma; Y, yes.
will result in lower CMMC numbers if anti-CD138 alone is used to capture cells after 24 h of sample collection. The CMMC numbers in the assay need to be constant up to 72 h after collection in order to make it practical for clinical samples because fresh samples are not always available. To improve assay reproducibility during sample storage, an additional capture antibody (CD38) was added to capture CMMC. In this way, CMMC capture is not dependent on only CD138 antigen. It is possible that inclusion of additional capture antibodies, such as CS1 (SLAMF7) in the kit could further improve the stability of CMMC capture under various clinical scenarios (Gross and Rao, unpublished observations). Molecules, such as CD38, which were used to capture and/or identify CMMC in this assay, are also targets for modern monoclonal antibody therapies, such as daratumumab. To minimize any potential interference of these therapies with the assay, additional combinations of antibodies may be incorporated which target plasma cell markers not targeted by therapies, and/or using antibodies that detect different epitopes of the target molecule than the therapeutic.
Whatever capture and detection reagents are selected; it is critical to confirm that isolated CMMC are of tumour origin to ensure their utility in disease assessment. Our finding that pools of manually isolated CMMC express myeloma genes provides one level of evidence that the CMMC are indeed malignant. Further evidence of the malignant nature of CMMC was provided by the high degree of concordance between CMMC FISH results and bone marrow analysis in cohorts of newly diagnosed MM and high/intermediate risk SMM. The confirmation of the malignant of nature CMMC begs the further exploration of CMMC as a surrogate for bone marrow as a means to understand tumour biology. We expect that pairing CMMC enrichment methods described here with recent advances in single cell isolation and sequencing techniques will enable more detailed comparison of bone marrow tumour cells versus CMMC. To this end, recently published single cell sequencing work by Lohr et al (2016) demonstrated that CMMC provide the same genetic information as bone marrow MM cells. These findings are consistent with our observations. Moreover, Lohr et al (2016) suggest that, in some cases, CMMC reveal mutations with greater sensitivity than bone marrow biopsies and allow classification of MM and quantitative assessment of genes that are relevant for prognosis. As we demonstrate in our study, the CELLSEARCH â CMMC assay is compatible with single cell CMMC analysis by NGS. We have shown that CMMC are elevated in all myeloma disease states relative to healthy donors. The occasional detection of plasma cells in the circulation of healthy donors is consistent with previous observations (Caraux et al, 2010) . It is not known whether the plasma cells detected in healthy donors in our study represent normal plasma cells that have escaped the bone marrow or if they represent an undiagnosed subclinical plasma cell disorder, such as MGUS. We have shown that CMMC are present at very low frequency in healthy donor blood and a standardized system may be of benefit in answering these questions.
In addition to the utility of CMMC as a research tool, we have observed a high degree of correlation between CMMC counts and disease burden in myeloma patients. In newly diagnosed MM, CMMC counts trended with M protein levels, percent bone marrow and ISS stage. We found an OS benefit for patients whose CMMC counts dropped to zero during remission. Likewise, we identified a population of patients with greater than 100 CMMC in remission that showed decreased OS despite achieving a suspected complete response in the clinic. The stratification of patients according to CMMC counts raises the possibility of using remission CMMC counts as a metric for minimal residual disease and as a surrogate endpoint for relapse in clinical trials.
In the SMM cohort, we found a significant association between CMMC counts and disease progression whereas routine measurements did not show a significant association. This confirms previous findings that CMMC have utility as a predictive tool in the SMM setting (Bianchi et al, 2013) . Use of a standardized CMMC assay to predict disease progression from SMM to active myeloma could have implications for disease management, including triggering more advanced diagnostics or starting treatment sooner.
The reproducibility, sensitivity, and non-invasive nature of the CMMC assay offers advantages over existing clinical and research tools. For example, we were able to robustly detect CMMC in peripheral blood samples when few or no CMMC could be detected by flow cytometry. While it is possible that advanced flow cytometry techniques could improve detection, flow-based methods are typically difficult to implement and standardize across institutions.
Recently, NGS-based approaches were utilized for detection of MM by tracking clonal IGH VDJ gene rearrangements (reviewed in (Mailankody et al, 2015) . While promising, the use of NGS for clone tracking-based detection of MM does not provide clinicians with information about genetic abnormalities associated with disease in a particular patient. Moreover, evolving clonal heterogeneity of the disease and/or clonal processes that often accelerate with age (such as monoclonal B-cell lymphocytosis, or clonal haematopoiesis of indeterminate potential) may complicate interpretation of results obtained with clone-tracking techniques, such as NGS (Mailankody et al, 2015; Szalat & Munshi, 2015 Nishihori et al, 2016) . Finally, current NGS testing works best with invasive bone marrow aspirates and may not have sufficient sensitivity to detect MRD in serum, plasma or peripheral blood (Mailankody et al, 2015) .
In conclusion, we developed a novel application for the FDA-approved rare cell enrichment platform, CELLSEARCH â . This application allows for isolation, enumeration and flexible molecular characterization of CMMC.
The data presented here demonstrate that CMMC can be used to study disease biology and monitor clinical disease progression through a blood draw. The non-invasive, easily 
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